December 20, 2021 7:12am
A holiday-shortened week - sector rotation adds to the sector’s direction difficulty
Pre-open indications: 12 SELLs
If you’re looking for sector intel, ideas and facts or Insight in a volatile climate, RMi defines the extenuating factors of share pricing! I follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all.”
Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.
Dow futures are DOWN -1.13% (-397 points), S&P futures are DOWN -1.23% (57 points) and NASDAQ futures are DOWN -1.3% (225 points)
Stock futures were lower in early morning pre-market trading Monday,
European markets fell sharply as the rapid spread of the omicron Covid-19 variant triggers stricter containment measures,
Asia-Pacific markets also fell with Japanese markets leading losses.
Henry’omics:
Indexes are coming off a negative week, with the S&P 500 declining 1.9%, Nasdaq dropping -3%, while the Dow slipped -1.7%.
The Russell 2000 hit a five-month low intraday Friday, but did reverse higher. Still, the Russell's strong decline over the past several months reflects the sharp deterioration in market breadth.
That's evident in the advance/decline line as well as new highs versus the mixed week of cell and gene therapy sector’s week as well.
Note: Moderna (MRNA) was higher by 5% after saying its vaccine booster dose provides significant protection against omicron.
- MRNA’s booster dose of its COVID-19 vaccine appears to be protective against the fast-spreading Omicron variant in laboratory testing and that the current version of the vaccine would continue to be Moderna’s "first line of defense against Omicron."
If you didn’t remember what happen at Friday night’s close, you won’t be prepared for today’s session:
Friday’s evening’s recap: “cell and gene therapy sector rotation in a frenetic and churning ascension. An expected rise to the upside having been stripped of value on Thursday from a repository of oversold with achievable upside; love those algorithms - today as differentiated from others” … https://www.regmedinvestors.com/articles/12232
Q4: December, 6 negative and 7 positive closes
- November, 1 holiday 5 positive and 16 negative close to date
- October, 8 positive and 13 negative closes
Companies in my headlights – It’s your decision; I provide an idea and context:
Probabilities versus aftermarket/pre-open share pricing indication moves:
SELL: Not in a “Santa Mood”
- Alnylam Pharmaceuticals (ALNY)
- AxoGen (AXGN)
- BioLife Solutions (BLFS)
- Cellectis SA (CLLS)
- CRISPR Therapeutics (CRSP)
- Editas Medicine (EDIT)
- Fate Therapeutics (FATE)
- Global Blood Therapeutics (GBT)
- Intellia Therapeutics (NTLA)
- Vericel (VCEL)
- Verastem (VSTM)
Never forget: Biostage (OTCQB: BSTG) closed down -$0.37 after Thursday’s flat $0.00 with 371 shares traded after Wednesday closed -$0.00 with 3,281 shares traded, Tuesday closed flat with 500 shares traded, Monday’s flat with 1 share traded, as last Friday closed up +$0.20 with 9,669 shares traded. Notice how the shares traded with and without the manipulated share pricing by volume stimulation.
The BOTTOM LINE: An outright market correction sends a clear signal - if you didn't get out, our sector is screwed.
A whipsaw market with a downside bias is extremely dangerous; it's an end-of-year environment that lures investors in, only to sell off sharply again.
I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis”.
RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.
WHY do I keep reporting on Biostage (BSTG): When one sees an inextricable wrong and morally repulsive scenario; it takes courage, resolve and patience to stay the course of asking the questions without response!
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
